[
    [
        {
            "time": "",
            "original_text": "【西南医药朱国广团队】药明康德（603259）限制性股票激励方案出台，建立长效机制",
            "features": {
                "keywords": [
                    "药明康德",
                    "限制性股票",
                    "激励方案",
                    "长效机制"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【西南医药朱国广团队】药明康德（603259）限制性股票激励方案出台，建立长效机制",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[增持评级] 药明康德(603259)上市公司简评：股权激励推动业绩增长 医药外包龙头中长期发展可期",
            "features": {
                "keywords": [
                    "药明康德",
                    "股权激励",
                    "业绩增长",
                    "医药外包",
                    "中长期发展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 药明康德(603259)上市公司简评：股权激励推动业绩增长 医药外包龙头中长期发展可期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[审慎增持评级] 药明康德(603259)点评：股权激励方案公布 为公司稳定发展奠基",
            "features": {
                "keywords": [
                    "药明康德",
                    "股权激励",
                    "稳定发展"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[审慎增持评级] 药明康德(603259)点评：股权激励方案公布 为公司稳定发展奠基",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]